Royal Bank of Canada
QNCX icon

Royal Bank of Canada’s Quince Therapeutics QNCX Stock Holding History

Royal Bank of Canada’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
+16
New +$3.21K ﹤0.01% 7575
2024
Q3 		– Sell
-1
Closed – – 7319
2024
Q2 		$0 Hold
1
– – ﹤0.01% 7441
2024
Q1 		$0 Hold
1
– – ﹤0.01% 7478
2023
Q4 		$0 Hold
1
– – ﹤0.01% 7491
2023
Q3 		$0 Sell
1
-1
-50% -$261 ﹤0.01% 7467
2023
Q2 		$1K Buy
+2
New +$623 ﹤0.01% 7061
2022
Q4 		– Sell
-15
Closed -$4K – 7619
2022
Q3 		$4K Buy
15
+3
+25% +$1.14K ﹤0.01% 6824
2022
Q2 		$5K Buy
12
+5
+71% +$3.53K ﹤0.01% 6661
2022
Q1 		$9K Sell
7
-17
-71% -$23.1K ﹤0.01% 7007
2021
Q4 		$61K Buy
24
+15
+167% +$91.5K ﹤0.01% 6251
2021
Q3 		$162K Sell
9
-23
-72% -$366K ﹤0.01% 5351
2021
Q2 		$337K Buy
32
+27
+540% +$226K ﹤0.01% 4624
2021
Q1 		$34K Buy
5
+4
+400% +$28.8K ﹤0.01% 6127
2020
Q4 		$4K Buy
+1
New +$8.86K ﹤0.01% 6743
2020
Q3 		– Hold
0
– – – 6468
2020
Q2 		– Hold
0
– – – 6472
2020
Q1 		– Hold
0
– – – 6321
2019
Q4 		– Hold
0
– -$2K – 7067
2019
Q3 		– Hold
0
– – – 6302

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada's QNCX Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Quince Therapeutics (QNCX) in Q1 2026: 16 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7575 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in QNCX as recently as Q2 2024.

Royal Bank of Canada first reported a position in QNCX in Q4 2020 and has held it in 14 quarters since. The position peaked at $337K in Q2 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Royal Bank of Canada held 16 shares of Quince Therapeutics worth $0 as of Q1 2026.
  • Quince Therapeutics was a new Royal Bank of Canada position in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7575 holding.
  • Royal Bank of Canada first reported a position in Quince Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • Royal Bank of Canada's Quince Therapeutics position peaked at $337K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.